Co-treatment of platelets and tumor cells with ifetroban, as well as pre-treatment of platelets with ifetroban, both resulted in decreased tumor cell-platelet interactions compared to untreated cells and in the presence of the TPr agonist U46619 (Fig. 2D-E). The gene discussed is TPR; the disease is neoplasm.